Retatrutide

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or swit

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)

TRIUMPH-1 is the pivotal Phase 3 master trial evaluating retatrutide (12 mg, 9 mg, 4 mg) versus placebo in adults with obesity or overweight, including subsets with knee osteoarthritis (GOA1) and obstructive sleep apnoea (GSA1). Top-line results announced by Eli Lilly on May 21, 2026: in 2,339 participants, retatrutide 12 mg produced a mean body weight reduction of 28.3% (average 70.3 lbs) over 80 weeks — a level historically associated with bariatric surgery. 45.3% of participants achieved ≥30% weight loss. In a 104-week extension subgroup (BMI ≥35), the 12 mg arm reached an average 30.3% loss (85.0 lbs). All three doses met primary and key secondary endpoints with significant improvements in cardiometabolic risk factors. Lilly plans to submit a New Drug Application to the FDA for retatrutide based on TRIUMPH programme data. Full results to be presented at the 86th ADA Scientific Sessions (June 2026).

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 vi

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin. For each participant, the study w

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight and Knee Osteoarthritis (TRIUMPH-4)

TRIUMPH-4 is a Phase 3, 68-week, randomised, double-blind, placebo-controlled study comparing retatrutide versus placebo in adults with obesity or overweight and knee osteoarthritis (OA). Participants received retatrutide 9 mg or 12 mg or placebo subcutaneously once weekly. Primary results announced December 2025: retatrutide 12 mg achieved 28.7% mean body weight reduction and a 75.8% reduction in WOMAC pain scores. Both co-primary endpoints met. 58.6% of 12-mg participants achieved ≥25% weight loss. Over 1 in 8 retatrutide-treated participants were completely free from knee pain at week 68.

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)

TRIUMPH-7 is a Phase 3, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last approximately 80 weeks. Part of the broader TRIUMPH Phase 3 programme evaluating retatrutide across multiple weight-related comorbidities.

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

TRANSCEND-T2D-2 is a Phase 3, randomised, multicenter, open-label study comparing the efficacy and safety of once-weekly retatrutide (LY3437943) versus once-weekly semaglutide in adults with type 2 diabetes and inadequate glycemic control on metformin with or without an SGLT2 inhibitor. Primary endpoint is HbA1c change at 40 weeks. Study duration approximately 26 months with up to 24 visits. Participants must have HbA1c 7.0–10.5% on stable metformin ≥1500 mg/day.

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

TRANSCEND-T2D-1 is a 40-week, Phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India evaluating once-weekly subcutaneous retatrutide (4 mg, 9 mg, or 12 mg) versus placebo as monotherapy in adults with type 2 diabetes inadequately controlled by diet and exercise alone (HbA1c 7.5–10.5%). Primary endpoint: change in HbA1c at week 40. Results published simultaneously in The Lancet and at the ADA 2026 Scientific Sessions (June 6, 2026, PMID 42250575): retatrutide reduced HbA1c by −1.69% (4 mg), −1.86% (9 mg), and −1.94% (12 mg) versus −0.81% placebo. The 12 mg dose produced 16.8% mean body weight loss (−36.6 lbs) with no plateau. Low discontinuation rates (2.2–5.1%). Phase 3 NDA submission anticipated based on TRIUMPH programme data.